The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,370.00
Bid: 12,370.00
Ask: 12,374.00
Change: 38.00 (0.31%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: UK Stocks Fall As US GDP Surge Turns Attention To Fed

Wed, 30th Jul 2014 16:34

LONDON (Alliance News) - UK stocks had a choppy trading session Wednesday and ultimately closed lower, while the dollar gained against other major currencies, as some heavily anticipated US GDP data showed the world's biggest economy more than reversed its first quarter slump.

The surprisingly strong US economy shifted the market focus squarely onto the Federal Reserve policy announcement still to come Wednesday.

The US economy grew at an annualised rate of 4.0% in the second quarter, more than reversing the 2.1% contraction in the first quarter, which was also revised up from the original 2.9% drop.

The data has been a long time coming for a market hoping for a sharp reversal in US economic growth following the first-quarter contraction, which was broadly blamed on particularly harsh winter weather. However, despite the reading causing an initial surge in global equity markets to session highs, investors have since reverted to caution ahead of a potential change of tone from the Federal Open Market Committee announcement at 1900 BST.

Concern over the potential economic impact of new sanctions from the EU and the US against Russia also have continued to weigh on general sentiment, and particularly the energy sector.

The FTSE 100 closed down 0.5% at 6,773.44 and the FTSE 250 down 0.4% at 15,629.84, while the AIM All-Share outperformed, closing up 0.1% at 772.25.

Within major European markets, the German DAX 30 ended down 0.6% and the French CAC 40 down 1.2%

After the European close, US markets continue to trade mixed, with the DJIA down 0.4%, the S&P 500 down 0.2%, and the Nasdaq Composite up 0.2%.

"The (US) data lends more credence to arguments that the Federal Reserve is nearing its mandates and this may bring forward speculation of when the Fed delivers its first rate hike," said Brown Brothers Harriman's Global Head of Currency Strategy Marc Chandler.

The dollar was the best performing currency in the wake of the bumper US GDP reading. The pound fell to the lowest level in six weeks, bottoming at USD1.6885, while the euro fell to its lowest level in more than eight months, bottoming at USD1.3364.

The UK banking sector provided the main downside support to the FTSE 100 after Barclays followed in Royal Bank of Scotland's recent footsteps by releasing first-half results ahead of analyst expectations.

Barclays said it made a GBP3.35 billion adjusted pretax profit in the first six months of 2014, down from a GBP3.59 billion profit in the year before but ahead of the GBP2.96 billion consensus forecast. Barclays also updated as to its progress on capital ratios, with the CET1 ratio increasing to 9.9% and the PRA leverage ratio increasing to 3.4% in the first half.

"The shares have been terrible performers of late so the profit beat and good progress on capital should come as a welcome relief to the market," said Shore Capital analyst Gary Greenwood.

Barclays ended as the top FTSE 100 gainer, up 4.5%, while RBS closed up 2.8%, and Lloyds, which reports its own results on Thursday, closed up 1.0%.

The bank shares envinced little concern over new Bank of England proposals, unveiled Wednesday, to increase individual responsibility and accountability in the banking sector, with changes including a new approval regime for the most senior bankers and new rules on bonuses.

Travis Perkins gained 2.7% after reporting a rise in pretax profit to GBP153.7 million in the first half, up 14% from the previous year, with the company citing improving market conditions and increased customer confidence. The group's consumer division, which incorporates DIY chain Wickes, saw revenue rise 8.8%.

Pets at Home was the top FTSE 250 gainer, closing up 7.1% after saying like-for-like sales were up 4.1% in the second quarter, boosted by a return to TV advertising and its VIP loyalty scheme. Despite the positive update, which boosted the Pets at Home to 182 pence Wednesday, the stock remains well below its March IPO price of 245p.

Mining stocks weighed on the other end of the market, led lower by Antofagasta, which closed down 4.6% at the bottom of the FTSE 100 after reporting production rates in line with expectations, but also a 16% rise in its net cash costs. Antofagasta has generally underperformed the other copper miners so far this year, which analysts attribute to its significant cost inflation.

Although the new sanctions from the EU and the US on Russia over its hand in the crisis in Ukraine are still short on details, the knowledge that they are on the way kept the energy sector in the red, with Royal Dutch Shell, BG Group, and BP down 1.8%, 1.8%, and 0.5%, respectively.

Given Fed Chair Janet Yellen's insistence that future monetary policy is not on a pre-set course and instead is data-dependent, it would not be unreasonable to expect a shift in the tone of the statement given the bumper US GDP reading just released.

While the statement, which follows the FOMC's two-day meeting, will be closely watched for such a change, it is highly unlikely that the central bank will deviate from the path of tapering asset purchases, and another USD10 billion cut is widely expected, which would leave the Fed on course to finish its quantitative easing programme in October.

Given Yellen's recent comment that US social media stocks are looking stretched, she and her colleagues at the FOMC will no doubt have watched with interest as Twitter jumped another 25% at the opening bell Wednesday, after announcing a huge extension of its user base, which grew by 16 million in the second quarter, adding huge future advertising potential.

Looking towards Thursday, while any unexpected commentary from the Federal Reserve has the potential to provide an early driver for markets, European data will be in focus, with unemployment numbers from across the region due throughout the morning and July eurozone CPI released at 1000 BST.

Another busy day in the UK corporate calendar Thursday brings interim results from Lloyds Banking Group, as well as its recently spun-off retail arm TSB Group. While it's the first update from TSB since its late June flotation, the expectations for Lloyds has been raised by the strong results reported Wednesday and last Friday by peers Barclays and Royal Bank of Scotland.

Drinks giant Diageo is scheduled released full-year results Thursday, while other names with interim results slated include BG Group, Centrica, AstraZeneca, BAE Systems, Rolls-Royce, Weir Group, Countrywide, and Intu Properties.

By Jon Darby; jondarby@alliancenews.com; @jondarby100

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.